- Home
- EVTV vs CUE Comparison
EVTV vs CUE Comparison
Compare EVTV & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVTV | CUE |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 17.6M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EVTV | CUE |
|---|---|---|
| Price | $1.78 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 368.3K | ★ 21.4M |
| Earning Date | 04-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | $5,939,008.00 | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 217.58 | 195.75 |
| 52 Week Low | $0.15 | $0.17 |
| 52 Week High | $5.07 | $1.03 |
Technical Indicators
Market Signals| Indicator | EVTV | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 61.47 |
| Support Level | $1.63 | $0.24 |
| Resistance Level | $2.40 | $0.84 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 37.78 | 66.62 |
Price Performance
Historical ComparisonAbout EVTV Envirotech Vehicles Inc.
Envirotech Vehicles Inc is a provider of purpose-built zero-emission electric vehicles focused on reducing the total cost of vehicle ownership and helping fleet operators unlock the benefits of green technology. It recognizes revenue from the sales of zero-emission electric vehicles and vehicle maintenance and inspection services. The Company serves commercial and last-mile fleets, school districts, public and private transportation service companies and colleges and universities to meet the increasing demand for light to heavy-duty electric vehicles.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.